Basilea Bids Farewell To Oncology To Focus On Anti-Infectives
Puts Faith In US Approval Of Antibiotic Zevtera
Executive Summary
Derazantinib, a promising fibroblast growth factor kinase inhibitor, is one of the cancer assets the Swiss firm is preparing to sell off, either separately or in a bundle, as it focuses on anti-infectives.
You may also be interested in...
Basilea Stresses Derazantinib's FGFR Kinase Differentiation
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Basilea's Ceftobiprole On TARGET, Needs Positive Second Study For US
The first pivotal Phase III study required for US approval of Basilea’s ceftobiprole has reported positive topline results; a second study is expected to read out in 2021.
Argenx Eyes Hat-Trick Of Successful Launches For Vyvgart After CHMP Thumbs-Up
Anant Murthy, general manager of Argenx Europe, tells Scrip that the commercial infrastructure is in place for Vyvgart to enjoy a strong launch for the rare neuromuscular disorder which will mirror those seen in the US and Japan.